Vemurafenib
Information
- Drug Name
- Vemurafenib
- Description
- Entry(CIViC)
- 110
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01659151 | Active, not recruiting | Phase 2 | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | August 3, 2012 | December 2024 |
| NCT03224767 | Active, not recruiting | Phase 2 | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | August 4, 2017 | August 2026 |
| NCT04591431 | Active, not recruiting | Phase 2 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | October 7, 2020 | June 2025 |
| NCT03101254 | Active, not recruiting | Phase 1/Phase 2 | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | June 6, 2017 | December 31, 2023 |
| NCT02908672 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | January 13, 2017 | May 15, 2024 |
| NCT01711632 | Active, not recruiting | Phase 2 | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | October 2012 | October 2025 |
| NCT03498521 | Active, not recruiting | Phase 2 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | July 10, 2018 | June 9, 2024 |
| NCT01748149 | Active, not recruiting | Early Phase 1 | Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas | April 29, 2014 | December 31, 2025 |
| NCT02314481 | Active, not recruiting | Phase 2 | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | May 12, 2017 | May 2026 |
| NCT03220035 | Active, not recruiting | Phase 2 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | November 8, 2017 | September 22, 2024 |
| NCT02304809 | Active, not recruiting | Phase 2 | Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations | October 13, 2014 | October 13, 2027 |
| NCT02721459 | Active, not recruiting | Phase 1 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | September 7, 2016 | October 2024 |
| NCT03181100 | Active, not recruiting | Phase 2 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | July 27, 2017 | July 31, 2025 |
| NCT03410875 | Active, not recruiting | Phase 2 | A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | February 9, 2018 | January 2025 |
| NCT01787500 | Active, not recruiting | Phase 1 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | February 15, 2013 | March 31, 2026 |
| NCT02145143 | Active, not recruiting | N/A | Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | May 2014 | May 2025 |
| NCT02036086 | Active, not recruiting | Phase 2 | Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | August 2015 | January 31, 2024 |
| NCT01909453 | Active, not recruiting | Phase 3 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma | September 16, 2013 | July 15, 2024 |
| NCT01689519 | Completed | Phase 3 | A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma | January 8, 2013 | July 21, 2019 |
| NCT01739764 | Completed | Phase 4 | An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | February 19, 2013 | February 17, 2020 |
| NCT01765543 | Completed | Phase 1 | A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) | July 2013 | November 2015 |
| NCT01765569 | Completed | Phase 1 | A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | July 2013 | June 2014 |
| NCT01767623 | Completed | Phase 1 | A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants | August 20, 2013 | April 20, 2017 |
| NCT01781026 | Completed | Phase 2 | Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | April 2013 | June 2014 |
| NCT00949702 | Completed | Phase 2 | A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | September 30, 2009 | June 3, 2014 |
| NCT01006980 | Completed | Phase 3 | A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | January 2010 | July 2015 |
| NCT01271803 | Completed | Phase 1 | A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | February 17, 2011 | December 12, 2017 |
| NCT01286753 | Completed | Phase 2 | A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation | June 2011 | May 2015 |
| NCT01307397 | Completed | Phase 3 | A Study of Vemurafenib in Participants With Metastatic Melanoma | March 1, 2011 | February 24, 2016 |
| NCT01378975 | Completed | Phase 2 | A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | July 2011 | July 2015 |
| NCT01524978 | Completed | Phase 2 | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | April 12, 2012 | October 28, 2016 |
| NCT01531361 | Completed | Phase 1 | Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations | February 6, 2012 | January 13, 2021 |
| NCT01596140 | Completed | Phase 1 | Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | December 18, 2012 | June 1, 2020 |
| NCT01597908 | Completed | Phase 3 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma | June 4, 2012 | April 25, 2019 |
| NCT01603212 | Completed | Phase 1 | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | July 18, 2013 | July 5, 2017 |
| NCT01636622 | Completed | Phase 1 | Study of Vemurafenib, Carboplatin, and Paclitaxel | July 9, 2012 | April 21, 2020 |
| NCT01636908 | Completed | N/A | Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | August 2011 | December 1, 2019 |
| NCT01656642 | Completed | Phase 1 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | August 13, 2012 | March 25, 2020 |
| NCT01657591 | Completed | Phase 1 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | July 27, 2012 | September 21, 2021 |
| NCT01667419 | Completed | Phase 3 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma | September 24, 2012 | July 13, 2018 |
| NCT01673737 | Completed | Phase 1 | A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer | August 2012 | February 2015 |
| NCT01673854 | Completed | Phase 2 | Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | September 13, 2012 | May 12, 2015 |
| NCT01844674 | Completed | Phase 1 | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | September 2, 2013 | August 26, 2014 |
| NCT01849666 | Completed | Phase 1 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | September 2013 | April 2014 |
| NCT01851824 | Completed | Phase 1 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | August 2013 | June 2014 |
| NCT01910181 | Completed | Phase 1 | A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | August 17, 2013 | April 20, 2018 |
| NCT01943422 | Completed | Phase 1 | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | October 2013 | December 2016 |
| NCT01959633 | Completed | Phase 1/Phase 2 | Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation | April 3, 2014 | March 26, 2018 |
| NCT02091141 | Completed | Phase 2 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | April 14, 2014 | May 24, 2023 |
| NCT02164916 | Completed | Phase 2 | S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | November 2014 | November 19, 2020 |
| NCT02291289 | Completed | Phase 2 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | April 17, 2015 | March 24, 2021 |
| NCT02354690 | Completed | Phase 1/Phase 2 | Vemurafenib and TIL Therapy for Metastatic Melanoma | November 2014 | December 31, 2018 |
| NCT02441465 | Completed | Phase 1 | Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies | August 13, 2015 | January 9, 2017 |
| NCT02456701 | Completed | Phase 1 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | June 2015 | October 13, 2016 |
| NCT02608034 | Completed | Phase 1 | A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | May 26, 2016 | September 10, 2018 |
| NCT02768207 | Completed | Phase 2 | A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | May 23, 2016 | June 27, 2019 |
| NCT02902029 | Completed | Phase 2 | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | November 2016 | March 2024 |
| NCT03013491 | Completed | Phase 1/Phase 2 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | January 2017 | October 6, 2021 |
| NCT03139513 | Completed | A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) | October 27, 2016 | August 22, 2018 | |
| NCT03625141 | Completed | Phase 2 | A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases | December 13, 2018 | April 13, 2023 |
| NCT04462471 | Completed | Phase 1 | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | June 26, 2020 | September 29, 2023 |
| NCT04790448 | Completed | Phase 1/Phase 2 | Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer | July 27, 2020 | December 31, 2021 |
| NCT05260684 | Completed | Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | January 17, 2022 | December 31, 2023 | |
| NCT03178552 | Recruiting | Phase 2/Phase 3 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | September 22, 2017 | August 3, 2028 |
| NCT05068752 | Recruiting | Phase 2 | Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer | October 28, 2021 | December 30, 2024 |
| NCT05525858 | Recruiting | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | September 28, 2022 | September 2025 | |
| NCT01638676 | Recruiting | Phase 1/Phase 2 | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | July 2012 | June 2027 |
| NCT05159245 | Recruiting | Phase 2 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | December 10, 2021 | November 25, 2026 |
| NCT03768063 | Recruiting | Phase 3 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | February 28, 2019 | July 5, 2028 |
| NCT04551521 | Recruiting | Phase 2 | CRAFT: The NCT-PMO-1602 Phase II Trial | October 13, 2021 | June 30, 2025 |
| NCT05233332 | Recruiting | Phase 2 | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) | February 24, 2022 | July 20, 2024 |
| NCT05768178 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | March 1, 2023 | October 2029 |
| NCT03554083 | Recruiting | Phase 2 | Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma | October 5, 2018 | June 29, 2025 |
| NCT05263453 | Recruiting | Phase 2 | HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | September 6, 2021 | December 31, 2024 |
| NCT03585686 | Recruiting | Phase 2 | A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation | June 26, 2018 | December 2023 |
| NCT03781219 | Recruiting | Phase 1 | A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation | July 1, 2018 | December 1, 2023 |
| NCT04943198 | Recruiting | Phase 2 | Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis | April 1, 2021 | June 23, 2026 |
| NCT06440850 | Recruiting | Phase 2 | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | November 30, 2024 | November 30, 2026 |
| NCT03155620 | Recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | July 31, 2017 | September 30, 2027 |
| NCT03430947 | Terminated | Phase 2 | Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | July 1, 2018 | February 10, 2023 |
| NCT04801966 | Terminated | N/A | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | September 23, 2021 | December 30, 2022 |
| NCT02818023 | Terminated | Phase 1 | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | July 13, 2016 | April 23, 2021 |
| NCT01616199 | Terminated | Phase 1/Phase 2 | Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma | August 2012 | March 2015 |
| NCT01611675 | Terminated | Phase 1 | Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | July 2012 | January 2014 |
| NCT01586195 | Terminated | Phase 2 | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | October 31, 2011 | April 30, 2015 |
| NCT01585415 | Terminated | Phase 1 | Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | April 9, 2012 | July 21, 2016 |
| NCT03224208 | Terminated | Phase 2 | Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients | May 17, 2018 | January 8, 2021 |
| NCT01519323 | Terminated | Phase 1 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | January 2013 | December 2015 |
| NCT01495988 | Terminated | Phase 2 | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | August 2013 | June 2016 |
| NCT01754376 | Terminated | Phase 2 | Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | January 2013 | March 2016 |
| NCT01474551 | Terminated | Phase 2 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | November 2011 | March 2013 |
| NCT01942993 | Terminated | Phase 2 | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | September 2013 | November 2015 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT01826448 | Terminated | Phase 1 | A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma | November 5, 2013 | September 22, 2014 |
| NCT02050321 | Terminated | Phase 2 | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | December 2013 | July 2015 |
| NCT02052193 | Terminated | Phase 2 | Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | January 2014 | December 15, 2014 |
| NCT01813214 | Terminated | Phase 2 | The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma | March 2013 | December 2016 |
| NCT02230306 | Terminated | Phase 2 | Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | February 2015 | March 2016 |
| NCT01400451 | Terminated | Phase 1 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | November 2011 | December 2013 |
| NCT02303951 | Terminated | Phase 2 | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | January 22, 2015 | May 14, 2020 |
| NCT01835184 | Terminated | Phase 1 | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | May 2013 | |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT03727763 | Unknown status | Phase 2 | Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) | October 8, 2018 | December 31, 2022 |
| NCT03239015 | Unknown status | Phase 2 | Efficacy and Safety of Precision Therapy in Refractory Tumor | January 1, 2017 | December 31, 2023 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT01974258 | Withdrawn | Phase 1 | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | February 2014 | July 2014 |
| NCT01843738 | Withdrawn | Phase 1 | Radiation Use During Vemurafenib Treatment | June 2017 | August 2022 |
| NCT01765556 | Withdrawn | Phase 1 | A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | October 2013 | October 2013 |
| NCT02145910 | Withdrawn | Phase 1 | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | ||
| NCT02427893 | Withdrawn | Phase 3 | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | August 2015 | November 2016 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Zelboraf
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2011
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2014
- Target (Drug list of Screening Committee of Anticancer Drugs)
- BRAF(V600E)
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- メラノーマ(BRAF/V600E)